Evidence map›Paper›PMID 31677380›Full record

ArticleThe Journal of infectious diseases2020

Targeting Parasite-Produced Macrophage Migration Inhibitory Factor as an Antivirulence Strategy With Antibiotic-Antibody Combination to Reduce Tissue Damage.

Swagata Ghosh, Jay Padalia, Renay Ngobeni, Jan Abendroth, Laura Farr, Debbie-Ann Shirley, Thomas Edwards, Shannon Moonah

Open access · hybridAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Membranes · 2022
    Review
  4. A Comprehensive Study on the Antimicrobial Properties of Resveratrol as an Alternative Therapy.Evidence-based complementary and alternative medicine : eCAM · 2021
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Swagata GhoshDepartment of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.
Jay PadaliaDepartment of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.
Renay NgobeniDepartment of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.
Jan AbendrothSeattle Structural Genomics Center for Infectious Disease, Seattle, Washington, USA.
Laura FarrDepartment of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.
Debbie-Ann ShirleyDepartment of Pediatrics, University of Virginia Health System, Charlottesville, Virginia, USA.
Thomas EdwardsSeattle Structural Genomics Center for Infectious Disease, Seattle, Washington, USA.
Shannon MoonahDepartment of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.
University of Virginia Health System · USCenter for Infectious Disease Research · US

Funding

STRUCTURE/FUNCTION OF E HISTOLYTICA ADHERENCE LECTINR01AI026649 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI PETRI, WILLIAM A · 1989 to 2016
$6.1M
Global Infectious Disease Research Training Program at UVAD43TW006578 · FIC · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GUERRANT, RICHARD L · 2003 to 2018
$2.7M
Role of the Pro-inflammatory MIF Homolog of Entamoeba histolytica in ColitisK08AI119181 · NIAID · UNIVERSITY OF VIRGINIA · PI MOONAH, SHANNON · 2016 to 2020
$946k
FIC NIH HHS D43 TW006578NIAID NIH HHS HHSN272201700059CNIAID NIH HHS K08 AI119181NIAID NIH HHS R01 AI026649NIH HHS HHSN272201700059C
6 · The paper itself

Abstract

Targeting virulence factors represents a promising alternative approach to antimicrobial therapy, through the inhibition of pathogenic pathways that result in host tissue damage. Yet, virulence inhibition remains an understudied area in parasitology. Several medically important protozoan parasites such as Plasmodium, Entamoeba, Toxoplasma, and Leishmania secrete an inflammatory macrophage migration inhibitory factor (MIF) cytokine homolog, a virulence factor linked to severe disease. The aim of this study was to investigate the effectiveness of targeting parasite-produced MIF as combination therapy with standard antibiotics to reduce disease severity. Here, we used Entamoeba histolytica as the model MIF-secreting protozoan, and a mouse model that mirrors severe human infection. We found that intestinal inflammation and tissue damage were significantly reduced in mice treated with metronidazole when combined with anti-E. histolytica MIF antibodies, compared to metronidazole alone. Thus, this preclinical study provides proof-of-concept that combining antiparasite MIF-blocking antibodies with current standard-of-care antibiotics might improve outcomes in severe protozoan infections.

Indexed as

Antiprotozoal AgentsAnimalsAntibodies, ProtozoanEntamoeba histolyticaEntamoebiasisHCT116 CellsHost-Parasite InteractionsHumansMacrophage Migration-Inhibitory FactorsMiceModels, MolecularProtozoan ProteinsAntibodies, ProtozoanAntiprotozoal AgentsMacrophage Migration-Inhibitory FactorsProtozoan ProteinsantibioticantibodyantivirulenceimmunopathologyimmunotherapeuticMIFparasite–host interactionsprotozoantissue damagevirulence

Identifiers

PMID31677380
PMCPMC7325720
OpenAlexW2984144960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.